In addition, our results showed that the ability of EGFR‐mutant and wild‐type NSCLC cell lines to form ERCC1 foci in response to cisplatin correlated with their survival after cisplatin treatment (Fig 2c). This evidence concerns the gene EGFR and non-small cell lung carcinoma.